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Genetic therapies for cystic fibrosis (CF) must be assessed for safety and efficacy, so testing in a non-human
primate (NHP) model is invaluable. In this pilot study we determined if the conducting airways of
marmosets (n 5 2) could be transduced using an airway pre-treatment followed by an intratracheal bolus
dose of a VSV-G pseudotyped HIV-1 based lentiviral (LV) vector (LacZ reporter). LacZ gene expression
(X-gal) was assessed after 7 days and found primarily in conducting airway epithelia as well as in alveolar
regions. The LacZ genewas not detected in liver or spleen via qPCR.Vector p24 protein bio-distribution into
blood was transient. Dosing was well tolerated. This preliminary study confirmed the transducibility of
CF-relevant airway cell types. The marmoset is a promising NHP model for testing and translating genetic
treatments for CF airway disease towards clinical trials.
T
he relentless progression of cystic fibrosis (CF) airway disease remains an unresolved problem although the
rate of decline has been slowed by the range of treatments now available. The majority of morbidity and
mortality relates to the chronic airway infection and inflammation that commences in early infancy and
leads to premature death from lung failure.
Gene-based correction of defective airway epithelial cell function, by introduction of the functional CF trans-
membrane conductance regulator (CFTR) gene, is a rational approach designed to produce lasting therapeutic
benefit and could be the basis for a cure. Practical success would restore CFTR ion-channel function, producing a
physiologically-balanced treatment for CF airway disease. Additionally, CFTR gene transduction of airway stem/
progenitor cells should produce extended correction because the daughter cells that re-populate the airway
epithelium contain the corrected CFTR gene1. Early correction, when CF lungs are considered to be functionally
unaffected2, has the potential to prevent the initiation of CF lung disease.
Inmice our single-dose lentiviral (LV) airway gene transfer technique produces immediate as well as long-term
airway reporter gene transfer3, extending up to a mouse lifetime. Use of a lysophosphatidylcholine (LPC) airway
pre-treatment improves gene transfer and may enable access to airway stem/progenitor cells able to support long
term gene expression4. Importantly, this method has already shown its utility with the therapeutic CFTR gene; we
have reported more than 12 months of functional CFTR gene expression in CFmouse airways5. Furthermore, we
have demonstrated robust reporter gene transfer in mouse lung and produced low-level proof-of-principle
expression in sheep lung6.
The aim of this pilot study was to test the potential of this method in the lungs of a non-human primate (NHP),
the marmoset (Callithrix jacchus). The marmoset has a number of advantages as a NHP animal model for
studying lung gene transfer. In particular, due to its small size, similar in body size to a very large rat, the modest
LV volumes required are within the capabilities of current vector production methods.
Results
This preliminary study was designed to establish if our LV vector delivery system could transduce NHP con-
ducting airway tissue prior to proposing and designingmore extensive NHP gene transfer studies. For that reason
in this short-term study only two animals (one male and one female) were used. No experimental controls were
employed since published3,5–7 data and our previous studies inmice and sheep strongly indicate that none of these
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LPC and LV dose deliveries were uneventful. General behaviour
(demeanour, feeding, respiration) and auscultation findings were
within normal limits over the post-treatment study period. In both
animals the gross appearance of the lungs was unremarkable when
the chest was opened. Histological examination of lung tissue by a
veterinary pathologist showed no abnormalities (including cellular
infiltration) of consequence.
LacZ gene expression: Histology. One week post-dosing LacZ gene
expression was visible in excised lung tissue from both marmosets,
although the female showed a higher level of transduction (Figs. 1–3
from the female marmoset). Figure 1 shows an en face example of
LacZ gene expression in lung tissue. LacZ gene expression was
present primarily in surface and basal epithelial cells in the
conducting airways. The patchy blue cell staining had a generally
peribronchiolar distribution along conducting airways in several
lobes (Fig. 1). In cross-sections of the trachea (Fig. 2) patchy
transduction was observed across the full thickness of the epithelium.
In the alveolar tissue (Fig. 3) there was substantially less cell trans-
duction present compared to the conducting airways. The trans-
duced cells in the distal lung airways included alveolar Type 1 and
Type II cells (Fig. 3b–c) and inflammatory cells such as alveolar
macrophages (Fig. 3d–e), and these were distributed across the lobes,
again in a patchy pattern. The macrophages displayed blue LacZ
staining indicating that both direct transduction and phagocytic
capture of transduced cells could occur.
Histological analysis of the liver and spleen samples showed no
LacZ gene expression.
LacZ gene presence: PCR. LacZ gene presence in the lung, liver and
spleen was assessed by quantitative PCR (qPCR). The LacZ gene was
detected in the lung tissue from the female marmoset (theDCt values
for the three tissue samples, performed in triplicate, were 11.91, 6.57
and 5.89), but not in the sampled lung tissue from themale. The LacZ
gene was not detected in the liver or spleen tissue from either
marmoset, nor in scavenged (untreated colony cull) marmoset
control tissue.
Vector particle dissemination. The protein p24 is a component of
the HIV-based LV vector virion, and its presence in blood was used
to determine the extent of non-target distribution of vector or vector
constituents after vector delivery into the airway. The levels of serum
p24 in both animals (Fig. 4) show that although the protein is found
in serum one day after dosing the levels declined therafter and
returned to baseline by day six.
Discussion
To our knowledge these are the first studies to test and show that
airway gene transfer can be achieved in vivo using a VSV-G pseudo-
Figure 1 | LacZ gene expression (blue stained cells) inmarmoset lung one
week after gene transfer. Transduction across several lobes occurred in an
airway-associated and a patchy-diffuse pattern. (a) Gene expression is
apparent in the intact trachea above the carina and adjacent to the upper
lobes seen here in the un-dissected lung after X-gal processing. (b) shows
an en face gross lobe section with blue stained cell patches distributed
around the lobe periphery. (c) In another thick en face section the patchy
peri-bronchioar distribution is evident, with the boxed region enlarged for
clarity in (d). Scale bars 2.5 mm.
Figure 2 | (a) Cross-sections show regions of patchy LacZ gene expression
along the trachea. The boxed areas in (a) are magnified in (b) and (c) to
show the nature of transduction of the conducting airway epithelium.
Examples of full thickness staining that includes basal cells (arrow heads),
surface and individual-cell gene expression are shown. In (d) the next serial
section adjacent to that shown in (c) is counterstained with Safranin-O and
more clearly displays the epithelial layer staining. H&E stain in (a), (b), and
(c). Scale bars 100 mm.
Figure 3 | 7-day LacZ gene expression in the alveolar region.
(a) A grouping of LacZ-expressing alveolar cells are present together with
an alveolar macrophage (arrow). Examples of (b) Type I pneumocyte
transduction, and (c) Type II pneumocyte transduction of several adjacent
cells with strong nuclear LacZ staining that has bled into the cytoplasm;
(d) and (e) show examples of alveolar macrophage staining showing
evidence of phagocytic LacZ staining (blue granules within the cytoplasm)
and direct cellular transduction (blue nuclear staining; arrow),
respectively. Scale bar 50 mm.
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typed HIV-based LV vector in an adult NHP model. Our findings
extend earlier work in human airway cell cultures and tracheal
explants showing efficient transduction with an Ebola-pseudotyped
HIV vector8, and airway transduction in infant macaques after in
utero parenchymal lung injection of a VSV-G pseudotyped HIV-
based vector9. The primary finding was that the marmoset lung
can be transduced using our LV vector delivery system. Based on
our behavioural assessments, gross post mortem organ examination,
and histological analysis, no adverse effects of either LPC or the LV
vector were apparent. As this was a limited observational pilot-study
design there were insufficient numbers of animals to provide detailed
quantitative comparisons.
The patchy gene expression observed in both marmosets has also
been observed in mice and sheep6 when fluid-based gene vector
dosing was used. This may be caused by multiple factors including,
but not limited to, incomplete coverage of the large surface area of the
lung airways by the relatively small dose volume, specificity of the
vector for particular cell types, and amismatch in the areas treated by
the LPC and LV vector doses. Importantly, the patchiness that would
accompany LV-CFTR vector dosed in the sameway does not prevent
physiologically functional CFTR gene expression occurring in our
CF mouse nasal airway studies3,5.
Ciliated airway surface epithelial cells are a primary target of CF
gene therapies, but are terminally-differentiated10. Gene expression
will be lost when those cells undergo apoptosis as part of normal lung
cell turnover processes. The lifespan of these epithelial cells in the
marmoset is unknown, but transduction of stem/progenitor cells
may be important for producing long-term gene expression.
Studies in mice suggest that the epithelial stem/progenitor cells
responsible for regular regeneration of the conducting airway epi-
thelium reside, in part, in the epithelial basal-cell compartment11.
The transient permeabilisation that LPC imposes on epithelial cell
tight junctions4 can provide access to those deep lying basal cells.
Importantly, we detected LacZ gene expression in these deep lying
epithelial cells at 7 days, suggesting our LV vector can reach regions
where some niches of adult stem/progenitor cells are expected to
reside in mammalian airways12. Similarly, alveolar epithelial cells
and macrophages13 were also transduced, with the latter finding
extending the results in rodents to a NHP model.
LacZ gene expression was not detected via X-gal staining or qPCR
in any sub-epithelial tissues or in the liver or spleen. Although LacZ
positive cells were visible in the lungs of both animals, the negative
qPCR finding in the male may have been the result of the randomly
selected tissue samples not containing any LacZ transduced cells. The
finding of a transient presence of the vector protein component p24
in serum (Fig. 4) confirms that although LV vector or vector com-
ponents can reach the circulation they are rapidly removed.
Although even conventional lipid-based lung gene transfer events
can deliver vector DNA to non-target organs14, further studies are
required to elucidate the mechanisms and implications of any off-
target organ transduction.
While the finding of gene transfer and expression in airway epi-
thelial cells is clear, there are obvious limitations. The very small
group size and absence of control animals (other than scavenged
tissue for qPCR analyses) were deliberately chosen to prevent unwar-
ranted use of additional NHPs should reporter gene transfer had not
proven effective. With the success of this pilot study, future studies
now warrant the use of larger group sizes including control animals.
Studies should be designed to assess the longevity of gene expression,
and should include a LV-only treatment group to directly determine
the requirement for LPC in the production of both short and long-
term lung gene expression. Additional detailed biosafety assays and
physiological, behavioural, immunological and histological monitor-
ing must also be included.
In summary, this pilot study demonstrated the successful exten-
sion of our LV delivery technique into a NHP lung. In the translation
of basic and preclinical science into useful human therapies this
initial success validates the use of LV gene delivery into a NHP lung
and suggests marmosets could serve as a valuable pre-clinical model
for translational studies in respiratory medicine.
Methods
This multi-institutional study was approved by the Animal Ethics committees of the
Women’s and Children’s Health Network, South Australia; and Monash University,
Victoria. Two marmosets, one female (F: ,275 g) and one male (M: ,300 g) were
sourced from the marmoset colony of the NH&MRC National Primate Colony,
Monash University. Animal husbandry, experiments and subsequent monitoring
were performed under specialist NHP veterinarian supervision and care provided by
Monash Animal Services, Victoria, Australia.
Airway pre-treatment. Airway pre-treatment with LPC (Sigma Aldrich L4129,
prepared w/v in PBS) was given prior to a single airway gene transfer event. The LPC
concentration (0.1% w/v) was derived from mouse studies5,6 where effectiveness and
tolerability were previously established. LPC dose volumes (F: 200 ml and M: 350 ml)
were calculated by scaling-up our successful mouse lung gene transfer doses6.
Gene vector. The nuclear-localised LacZ (NLS-LacZ) VSV-G pseudotyped HIV-1
based LV vector was a 5-plasmid non-replicating SIN vector produced according to
previously published methods5,15. Virus titre was 1.23 109 viral genome equivalents
per ml as assayed by quantitative PCR7. The LV vector volumes (F: 350 ml and
M: 500 ml) were also estimated by scale-up from our mouse deliveries.
Pre-treatment and LV dosing. Anaesthetic induction was with 10 mg/ml alfaxalone
(JuroxRutherford, NSW,Australia) and animals were intubatedwith an endotracheal
tube (Sheridan Uncuffed 2.0, Hudson RCI, USA) placed with the tip midway between
the epiglottis and the carina. Anaesthesia was maintained using 1.25% – 1.5%
isofluorane. Dosing was performed in a Class II biosafety cabinet with animals held
supine throughout. The LV vector was delivered as a single fluid bolus to the trachea
via the endotracheal tube over ten seconds, one hour after the LPC pre-treatment.
Animals were held anaesthetised and supine in the cabinet for an additional hour after
LV dosing before being extubated and placed in PC-2 caging facilities.
Monitoring.Vital signs weremonitored throughout dosing and in the post-operative
period. Body weight and general behaviour were monitored daily along with blood
sampling (centrifuged at 13,000 rpm, with sera stored at 280uC until required).
Tissue harvesting. Animals were humanely killed at 7 days using an Alfaxalone
induction followed by pentobarbital overdose. The lungs were inflation-fixed in situ
in 2% paraformaldehyde/0.5% glutaraldehyde (PFA/Glut) in PBS at 4uC and a
pressure of 30 cmH2O for 15 mins. Samples of liver and spleen were also harvested
and fixed in PFA/Glut at 4uC.
LacZ gene expression: Histology. The lungs were then excised and submerged in
fresh chilled PFA/Glut overnight, and were subsequently processed for LacZ
expression by our standard X-gal staining method6. The extent of LacZ gene
expression in airway cells was first assessed en face in gross transversely-sectioned
portions of lung. Blocks that showed blue LacZ staining were then prepared for
routine histological sectioning with haematoxylin/eosin (H&E) or a Safranin-O
counterstain.
LacZ gene presence: qPCR. Triplicate tissue samples (20 mg) were selected from
random locations in the lungs, liver and spleen. Scavenged tissue from untreated
animals was used as a negative control. All lung samples were then incubated at 55uC
Figure 4 | p24 assay on marmoset serum demonstrates that the vector
components are present in the blood shortly after dosing, but are cleared
prior to day 7.
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overnight in tail lysis buffer (Viagen Biotech, USA, Cat. # AB102-T) and 20 mg/ml
Proteinase K (Promega, USA, Cat. # V3021) at a 1550 ratio then heated to 80uC for
one hour and crude lysates were stored at 220uC until analysis. All other samples
were processed via the Wizard SV Genomic DNA Purification System (Promega,
USA, Cat. # A2361) according to manufacturers specifications.
qPCR for the NLS-LacZ gene and marmoset GAPDH housekeeping gene16 was
performed in a 96 well plate format (CFX Connect Real-Time PCR, Bio-Rad)
according to the manufacturers standard protocol. Specific amplification was
detected using SYBRGreen (Fast SYBRGreenMaster Mix, Applied Biosystems USA,
Cat. # 4381562). Cycle thresholds (Ct) for the LacZ gene were normalised with respect
to the housekeeping gene and presented as DCt. The following primers were used:
NLS-LacZ forward GCC ACT TCT TGA TGG ACC ACT T, NLS-LacZ reverse CCG
CCACCGACATCA TCT, GAPDH forward AAAGTGGATGTCGTCGCC ATC
AAT GAT and GAPDH reverse CTG GAA GAT GGT GAT GGG ATT TCC ATT
(GeneWorks, Australia).
Vector particle dissemination. Sera were analysed using a HIV-1 p24 ELISA Kit
(Perkin Elmer Life Sciences USA Ca# NEK050) performed as per manufacturer
instructions.
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